Gilead Sciences has partnered with Jounce Therapeutics through a licensing deal for its cancer therapy drug, JTX-1811, with Jounce eligible for an upfront payment of $85 million plus a $35 million equity investment from Gilead. The deal could potentially bring in up to $685 million in milestone payments for Jounce.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.